2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMOWill not start
The ability to fuse discrete small molecules with different types of pharmacologic activity has created remarkable opportunities in drug discovery and development. Bendamustine itself is a fusion molecule of the nitrogen mustard mechlorethamine and…